Halota W, Flisiak R, Juszczyk J, et al. Recommendations of the Polish Group of Experts
for HCV for the treatment of hepatitis C in 2020. Clinical and Experimental Hepatology. 2020;6(3):163-169. doi:10.5114/ceh.2020.98606.
APA
Halota, W., Flisiak, R., Juszczyk, J., Małkowski, P., Pawłowska, M., & Simon, K. et al. (2020). Recommendations of the Polish Group of Experts
for HCV for the treatment of hepatitis C in 2020. Clinical and Experimental Hepatology, 6(3), 163-169. https://doi.org/10.5114/ceh.2020.98606
Chicago
Halota, Waldemar, Robert Flisiak, Jacek Juszczyk, Piotr Małkowski, Małgorzata Pawłowska, Krzysztof Simon, and Krzysztof Tomasiewicz. 2020. "Recommendations of the Polish Group of Experts
for HCV for the treatment of hepatitis C in 2020". Clinical and Experimental Hepatology 6 (3): 163-169. doi:10.5114/ceh.2020.98606.
Harvard
Halota, W., Flisiak, R., Juszczyk, J., Małkowski, P., Pawłowska, M., Simon, K., and Tomasiewicz, K. (2020). Recommendations of the Polish Group of Experts
for HCV for the treatment of hepatitis C in 2020. Clinical and Experimental Hepatology, 6(3), pp.163-169. https://doi.org/10.5114/ceh.2020.98606
MLA
Halota, Waldemar et al. "Recommendations of the Polish Group of Experts
for HCV for the treatment of hepatitis C in 2020." Clinical and Experimental Hepatology, vol. 6, no. 3, 2020, pp. 163-169. doi:10.5114/ceh.2020.98606.
Vancouver
Halota W, Flisiak R, Juszczyk J, Małkowski P, Pawłowska M, Simon K et al. Recommendations of the Polish Group of Experts
for HCV for the treatment of hepatitis C in 2020. Clinical and Experimental Hepatology. 2020;6(3):163-169. doi:10.5114/ceh.2020.98606.
The recommendations set out the principles of diagnosis and treatment of hepatitis C virus (HCV) infections according to the most recent knowledge. The main goal of therapy for HCV infection is to eliminate the virus from the body, which consequently leads to arrest of progress or regression of changes in the liver. Current version of the recommendations prioritise pangenotypic regimens and provide guidelines in special populations of patients, such as children, cirrhotics, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) coinfected, those with renal failure, hepatic decompensation and non-responders to previous therapies.
